



# CITURGIA BIOCHEMICALS LIMITED

**Regd. Office:** 6/C, Ostwal Park Building No. 4, Chsl, Near Jesal Park, Jain Temple,  
Bhayandar East, Thane-401105, Maharashtra. **CIN:** L24100MH1974PLC017773

**Website:** [www.citurgiabio.com](http://www.citurgiabio.com); **E-mail id:** citurgia\_bio@yahoo.com

**Date: 12<sup>th</sup> February, 2021**

**To,**

**BSE Limited**  
**P J Towers, Dalal Street**  
**Mumbai – 400001**  
**Scrip Code: 506373,**  
**Scrip ID: CITURGIA**


**Sub: Submission of Unaudited Financial Results for Quarter ended on 31<sup>st</sup> December, 2020.**

Dear Sir/Madam,

Pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015, Please find enclosed herewith Unaudited Financial Results for the Quarter ended on 31<sup>st</sup> December, 2020 along with Limited Review Report issued by the statutory auditor of the company as approved by the Board of Directors in their meeting held on 09<sup>th</sup> February, 2021.

We request you to kindly take the same in your record.

For CITURGIA BIOCHEMICALSLIMITED

  
AKSHOD KUMAR SHARMA  
WHOLE TIME DIRECTOR  
DIN: 02112607

**PART-I STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 31.12.2020**

Particulars		Quarter Ended			Period Ended		Year Ended
		3 Months ended 31/12/2020	Preceding 3 months ended 30/09/2020	Corresponding 3 months ended 31/12/2019	Year to Figure for current year ended 31.12.2020	Year to Figure for previous year ended 31.12.2019	Previous Year Ended 31/03/2020
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
I.	Total Income form Operations	-	-	-	-	-	-
II.	Other Income	-	-	-	-	-	-
III.	<b>Total Revenue (I+II)</b>	-	-	-	-	-	-
IV.	<b>Expenses</b>						
	a) Cost of Materials consumed	-	-	-	-	-	-
	b) Purchase of Stock-in-trade	-	-	-	-	-	-
	c) Changes in inventories of finished goods, WIP and stock in trade	-	-	-	-	-	-
	d) Employee benefits expenses	3.95	4.40	3.07	10.35	9.96	13.34
	e) Depreciation and amortisation expenses	5.97	5.96	6.92	17.89	20.76	32.09
	f) Other expenses	0.29	21.78	0.53	22.08	0.86	10.76
	<b>Total Expenses</b>	<b>10.21</b>	<b>32.14</b>	<b>10.52</b>	<b>50.32</b>	<b>31.57</b>	<b>56.18</b>
V	Profit/(Loss) before exceptional and extraordinary items and tax (III-V)	<b>(10.21)</b>	<b>(32.14)</b>	<b>(10.52)</b>	<b>(50.32)</b>	<b>(31.57)</b>	<b>(56.18)</b>
VI	Exceptional Items	-	-	-	-	-	-
VII	Profit/(Loss) before extraordinary items and tax (VI-VII)	(10.21)	(32.14)	(10.52)	(50.32)	(31.57)	(56.18)
VIII	Extraordinary items	-	-	-	-	-	-
IX	Profit/(Loss) before tax (VIII-IX)	(10.21)	(32.14)	(10.52)	(50.32)	(31.57)	(56.18)
X	Tax expenses						
	a) Current Tax	-	-	-	-	-	-
	a) Income Tax Adjustment	-	-	-	-	-	-
	a) MAT Credit Entitlement	-	-	-	-	-	-
	b) Deferred Tax Liabilities / (Assets)	-	-	-	-	-	-
XI	Profit (Loss) for the period from continuing operations (IX-X)	(10.21)	(32.14)	(10.52)	(50.32)	(31.57)	(56.18)
XII	Profit/(loss) from discontinuing operations	-	-	-	-	-	-
XIII	Tax expense of discontinuing operations	-	-	-	-	-	-
XIV	Profit/(loss) from Discontinuing operations (after tax) (XII-XIII)	-	-	-	-	-	-
XV	Profit (Loss) for the period (XI + XIV)	(10.21)	(32.14)	(10.52)	(50.32)	(31.57)	(56.18)
XVI	Other Comprehensive Income						
	A (i) Items that will not be reclassified to profit or loss	-	-	-	-	-	-
	(ii) Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-	-	-
	B (i) Items that will be reclassified to profit or loss	-	-	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
XVII	Total Comprehensive Income for the period (XV+XVI) (Comprising Profit (Loss) and Other	(10.21)	(32.14)	(10.52)	(50.32)	(31.57)	(56.18)

	Comprehensive Income for the period)						
XVIII	Earnings per equity share (for continuing operation):						
	(1) Basic	0.001	0.002	0.000	0.003	0.002	0.005
	(2) Diluted	0.001	0.002	0.000	0.003	0.002	0.005
XIX	Earnings per equity share (for discontinued operation):						
	(1) Basic	0.000	0.000	0.000	0.000	0.000	0.000
	(2) Diluted	0.000	0.000	0.000	0.000	0.000	0.000
XX	Earning Per Share (for discontinued & continuing operations)						
	a) Basic	0.001	0.002	0.000	0.003	0.002	0.005
	b) Diluted	0.001	0.002	0.000	0.003	0.002	0.005

**NOTES :**


1. The above results have been reviewed by the Audit Committee and approved by the Board of Directors in their meeting held on 09<sup>th</sup> February, 2021.

2. The previous period figures have been rearranged / regrouped, wherever necessary to confirm to current period classifications.

3. The financial results are subject to the Limited Review Report issued by the statutory auditors of the company.

4. The Financial Results have been prepared in accordance with the recognition and measurement principles laid down in the applicable Indian Accounting Standard (Ind AS) prescribed under Section 133 of the Companies Act, 2013, read with relevant rules there under in terms of Regulation 33 of SEBI (Listing and Disclosure Requirements) Regulations, 2015 and SEBI Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016.

For CITURGIA BIOCHEMICALSLIMITED

  
AKSHOD KUMAR SHARMA  
WHOLE TIME DIRECTOR  
DIN: 02112607

**Date : 09<sup>th</sup> February, 2021**

**Place : Mumbai**



# G.P. KESHRI & ASSOCIATES

## Chartered Accountants

Head Office: A-215/5, Chawla Complex, Vikas Marg, Shakarpur, New Delhi-110092 (Delhi)  
Phone: +91 011 22546181, Mobile: +91 9818433797, +91 8882710429, Fax: +91 011 22546181  
E-Mail: gopalkeshri@yahoo.com

### LIMITED REVIEW REPORT

To,  
Board of Directors of  
M/S Citurgia Biochemicals Limited

We have reviewed the accompanying statement of Unaudited Financial Results of M/S Citurgia Biochemicals Limited (the "Company"), for the quarter and period ended 31<sup>st</sup> December 2020, being submitted by the company pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. This Statement is the responsibility of the Companies Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the standard on Review Engagement (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditors of the Entity, issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is Limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus accordingly, we do not express and\ audit opinion.

Based on our review conducted as above, nothing has come to our attention that caused us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards i.e. Indian Accounting Standards prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued hereunder and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligation and disclosed Requirements) Regulations, 2015 and SEBI circular dated 5<sup>th</sup> July 2016 including the manner in which it is to be disclosed, or that its contains any material misstatement.

For G.P.Keshri & Associates.  
Chartered Accountants

CA. Gopal Prasad Keshri  
Partner  
FRN: 017251N  
M.NO: 098476  
UDIN:21098476AAAAAW7988

Place: New Delhi



Branch Offices:

Ghaziabad (U.P.)

Dhanbad (Jharkhand)